Management of hypertension in diabetic patients: outstanding issues

Abstract

Cardiovascular disease is the leading cause of premature mortality in Type 2 diabetes mellitus; consequently, good management of all risk factors is vital. The recent reappraisal of the European Society of Hypertension guidelines on hypertension management reset the blood pressure goal for Type 2 diabetic patients to blood pressure <140/90 mmHg. Although this recommendation is based on the best available evidence, further data are still required to provide a better understanding of the natural history of Type 2 diabetes in order to establish blood pressure goals throughout the natural history of the diabetic patient with hypertension.

Keywords::

• blood pressure control
• cardiovascular disease
• hypertension
• T2DM mellitus

Financial & competing interests disclosure

Miguel Camafort-Babkowski has received payment for consultancies and lecture fees from Menarini and Novo Nordisk, and is the national leader for Spain of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. Antonio Coca has received payment for board membership from Menarini, Novartis, Servier, sanofi-aventis and Bristol-Myers Squibb; lecture fees from Abbott, Bayer Schering Pharma, Novartis, Servier and Ferrer International; and payment for development of educational activities from Menarini and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Appendix 1

Table